Introduction
The modification of DNA bases occurs spontaneously during normal cell growth, and the rate of formation of modified bases increases considerably when cells are exposed to radiation and certain chemical agents. O 6 -methylguanine is one of such bases produced by the action of simple alkylating agents, such as N-methyl-N-nitrosourea (MNU) and N-methyl-N 0 -nitro-N-nitrosoguanidine (Beranek, 1990) . This modified base can pair with thymine as well as cytosine during DNA replication, and a G:C to A:T transition mutation ensues after two cycles of DNA replication (Coulondre and Miller, 1977; Loechler et al., 1984; Ito et al., 1994) . To prevent such outcomes, organisms possess a specific DNA repair enzyme, O 6 -methylguanine-DNA methyltransferase (MGMT), which transfers a methyl group from the O 6 -methylguanine moiety to its own molecule, thereby repairing the DNA lesion in a single-step reaction (Pegg, 2000; Margison and Santibanez-Koref, 2002; Kaina et al., 2007) . Mgmt À/À mice, which are defective in the methyltransferase gene, are hypersensitive to the killing effect of alkylating agents and suffer from severe damage in the bone marrow and intestinal mucosa, which are largely composed of rapidly growing cells (Tsuzuki et al., 1996; Sakumi et al., 1997; Glassner et al., 1999) . Studies with cell lines derived from Mgmt À/À mice further revealed that O 6 -methylguanine-induced cell death occurs by apoptosis, which requires at least one round of DNA replication for its induction (Tominaga et al., 1997; Meikrantz et al., 1998) .
A notable feature of O 6 -methylguanine-induced apoptosis is the requirement of mismatch repair (MMR) proteins, such as MSH2 and MLH1 (Hickman and Samson, 1999; Pepponi et al., 2003) . Studies with cell lines derived from human tumors revealed that the lack of some of these gene functions rendered MGMTdeficient cells resistant to alkylating agents (Branch et al., 1993; Kat et al., 1993) . Recent studies with Mgmt À/À Mlh1 À/À cells, derived from gene-targeted mice, have shown that the MLH1 protein is indeed required for the execution of apoptosis triggered by O 6 -methylguanine (Kawate et al., 1998; Takagi et al., 2003) . We have shown that MutSa, consisting of MSH2 and MSH6 proteins, and PCNA bind to O 6 -methylguaninecontaining DNA to form an initial complex, and MutLa, composed of MLH1 and PMS2, binds to this complex (Hidaka et al., 2005) . However, the precise mechanisms regarding how the MMR complex activates the apoptotic signal remain to be elucidated. Two hypotheses have so far been proposed: the MMR complex formed on chromatin might induce the apoptotic signal (Fishel, 1998) or abortive repair cycle initiated by the complex might lead to apoptosis (Karran, 2001) .
The activation of ATR kinase and phosphorylation of its downstream targets have been shown to take place in an MMR protein-dependent manner in cells treated with MNU (Caporali et al., 2004; Stojic et al., 2004; Sanada et al., 2007) . The MMR protein-dependent release of cytochrome c from mitochondria and activation of caspases, which are hallmarks for apoptosis, also occur in the case of O 6 -methylguanine-induced apoptosis (Ochs and Kaina, 2000; Takagi et al., 2003; Hickman and Samson, 2004) . As apoptosis caused by bulky DNA lesions that block DNA replication occurs even in cells deficient in MMR proteins (Peng et al., 2007; Sanada et al., 2007) , the apoptosis pathway induced by O 6 -methylguanine, which does not block DNA replication, appears to be distinct from the former. It is highly likely that other proteins are also involved in the pathway. Therefore, retrovirus-mediated gene-trap mutagenesis (Ishida and Leder, 1999; Wiles et al., 2000; Guo et al., 2004) was used to isolate a mutant, which exhibits an increased tolerance to a simple alkylating agent that produces O 6 -methylguanine. The disrupted gene in the mutant was identified to be a novel gene, designated Mapo1 (for O 6 -methylguanine-induced apoptosis 1), which encodes a protein with a molecular mass of 125.6 kDa. Evidence is herein presented, which shows that the protein might be involved in the pathway of apoptosis induced by O 6 -methylguanine adducts.
Results

Isolation of mutant cells defective in O 6
-methylguanineinduced apoptosis To perform insertional mutagenesis, we constructed a retrovirus-based gene-trap vector, pLHDU3L, as illustrated in the upper part of Figure 1 . The vector carries a promoterless hygromycin B resistance (Hyg r ) gene, together with a splice acceptor site and an internal ribosome entry site (IRES), which would facilitate efficient transcription and translation of the Hyg r gene when integrated into any region, including an intron sequence, of actively transcribed genes. If the function of any gene indispensable for inducing apoptosis is lost by this insertional mutagenesis, we may expect that Mgmtdefective cells that are hypersensitive to a simple alkylating agent would become resistant to MNU. According to this experimental scheme (Figure 1 O 6 -Methylguanine, which is a major cytotoxic adduct produced in DNA by treating the cells with low doses of MNU, can be repaired by a specific DNA repair enzyme, MGMT. As shown in Figure 2 , YT102 cells are defective in this enzyme and readily undergo cell death after exposure to relatively low doses of MNU. In contrast, YT102M, a derivative of YT102 that stably expresses human MGMT (Figure 2a) , is resistant to the treatment with such doses of MNU, indicating that the cell death induced in YT102 cells results from O 6 -methylguanine. One of the isolated mutants exhibited a significantly high level of resistance to MNU, in comparison to the parental cell line YT102, without expressing MGMT. The expression levels of MMR proteins, namely MSH2, MSH6, MLH1 and PMS2, which are required for the recognition of the O 6 -methylguanine-mispaired lesions, were not affected in the mutant (Figure 2a ). We termed this clone KH101 and performed a survival assay with various doses of MNU. As calculated from the survival curves shown in Figure 2b , the doses required to give LD 37 to KH101 and the parental Mgmt À/À strain, YT102, are 0.48 and 0.08 mM, respectively. Therefore, KH101 is approximately six times more resistant to MNU than the parental Mgmt À/À strain, due to inactivation of a certain gene that might be required for apoptosis. The level of resistance of KH101, however, is lower in comparison to YT103, which lacks both MGMT and MLH1 functions. When treated with other DNA-damaging agents, methyl methanesulfonate (MMS), 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), etoposide and ultraviolet (UV)-C, which produce primarily N7-methylguanines and N3-methyladenines, DNA-interstrand crosslinks, DNA double-strand breaks and pyrimidine dimers, respectively, KH101 cells showed a similar degree of sensitivity to the parental strain YT102, although KH101 cells tended to be slightly more resistant than YT102 in all cases. YT103 and YT102M cells displayed increased resistance to MMS in comparison to YT102, as reported earlier (Kaina et al., 1991; Glaab et al., 1998) . YT102 cells were quite resistant to ACNU as expected (Peng et al., 2007 ; -methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR) proteins in YT102, YT103, KH101 and YT102M cell lines. The MGMT and MMR proteins were detected with immunoblotting using specific antibodies. (b) The cells were treated with different concentrations of N-methyl-N-nitrosourea (MNU), methyl methanesulfonate (MMS) and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) for 1 h, or etoposide for 12 h, and then were incubated in a drug-free medium for 6 days. For ultraviolet (UV) irradiation, the cells were exposed to different doses of UV-C. The numbers of colonies were counted and the survival fractions were determined. All experiments were performed three times and the standard deviations are shown in bars. Open circles, YT102 (Mgmt
A new apoptosis-inducing protein, MAPO1 K Komori et al Sanada et al., 2007) . These results imply that KH101 cells might have a defect in a gene involved in the induction of cell death caused by MNU-induced O 6 -methylguanine.
MNU-induced mutant frequency
As O 6 -methylguanine is a premutagenic DNA lesions, the mutation frequency would increase if cells carrying O 6 -methylguanine are not eliminated by apoptosis (Takagi et al., 2003) . Therefore, we measured the mutant frequency of KH101 cells with respect to ouabain resistance, which can arise by a mutation in the Na þ /K þ ATPase locus ( Figure 3) . As a control, we used YT102M, which is resistant to MNU, for its overexpression of the human MGMT protein. Without MNU treatment, YT102M and KH101 cells exhibited the same low level of mutant frequency, indicating that the defect in KH101 cells does not affect the spontaneous mutagenesis. The mutant frequencies of both strains increased on exposure to MNU, but the extent of increase in KH101 was far greater than that of YT102M. The level attained with KH101 cells was about six times higher than that of YT102M. This is consistent with the possibility that the gene product defective in KH101 cells may be involved in a process to execute apoptosis in cells carrying mutation-evoking DNA lesions.
Identification of the gene defective in KH101 mutant
To determine the genomic sequence into which the vector DNA has been integrated, we carried out inverse PCR using the genomic DNAs digested with several restriction enzymes as templates. The amplified DNA fragments, spanning the junctions between the genomic DNA and the integrated vector sequences, were cloned into a pGEM-Teasy plasmid, and the nucleotide sequences were determined. A database search revealed that the vector DNA to be integrated in a sequence corresponding to the first intron of a putative gene mKIAA1450 (GenBank accession no. XM_907047) (Figure 4a ), located in the E3 locus of mouse chromosome 3. The prospective gene is composed of at least 18 exons and would encode a polypeptide comprising 1138 amino acids. The gene is novel, and thus, we named it Mapo1. A homology search shows that the MAPO1- A new apoptosis-inducing protein, MAPO1 K Komori et al related sequences are present in a wide range of multicellular organisms ranging from humans to nematode, but not found in microorganisms, including budding and fission yeasts. There are highly conserved sequences in the amino-and the carboxyl-terminal regions of the protein (Figure 4b ).
To determine whether either a single or both allele(s) of the gene was disrupted in the mutant, we performed PCR analyses using two sets of primers specific for the disrupted gene, G5 0 þ V5 0 and V3 0 þ G3 0 primers, and a G5 0 þ G3 0 primer set for the intact sequence of wild-type allele (Figure 4c ). In the sample from the KH101 mutant, signals for the 5 0 -and 3 0 -junctions of the Mapo1 gene and the vector DNA, and also a signal specific for the intact gene, were detected. In the sample derived from YT102, only a signal for the intact gene was found. These results suggest that one of the Mapo1 alleles was disrupted, whereas the other remains intact in KH101 cells. In proportion to the gene dosage, the expression level of the Mapo1 gene in KH101 (Mapo1 Suppression of the MAPO1 function by small interfering RNA A synthetic small interfering RNA (siRNA) for the Mapo1 gene, siMapo1, was introduced into YT102 cells and its expression level was determined 48 h later. An siRNA composed of a sequence unrelated to the Mapo1 gene was also introduced as a control. The expression level of the Mapo1 gene in siMapo1-treated cells was reduced to 43% of that of cells that received the control RNA, siCont (Figure 5a ). These two types of cells were treated with or without 1 mM MNU and, after incubation for 2, 3 and 4 days, were subjected to flow cytometric analysis to monitor the appearance of cells with a sub-G1 DNA content. After treatment with MNU, the sub-G1 cell population increased gradually in cells treated with either type of siRNA, but the degree of increase in cells treated with siRNA for Mapo1 was significantly lower than that obtained with control siRNA-treated cells (Figure 5b) . A similar result was obtained by using siRNA that binds to a different region of Mapo1 sequence (data not shown). Therefore, a good correlation was observed between the Mapo1 expression level and the sub-G1 population in cell culture after MNU treatment. As an increase in the sub-G1 population represents the number of cells that undergo apoptotic cell death, these results suggest that the MAPO1 function is involved in O 6 -methylguanineinduced apoptosis.
Effects of Mapo1 mutation on apoptosis-related events We analysed the levels of the phosphorylation of p53, CHK1 and histone H2AX (gH2AX), which are believed to be the downstream targets of ATR kinase, when the cells were treated with MNU (Cejka et al., 2003; Stojic et al., 2004) . As shown in Figure 6a , the MNU-induced phosphorylation of these proteins was clearly observed, We further examined the effect of Mapo1 mutation on the depolarization of the mitochondrial membrane, which is known to occur during the process of apoptosis (Cossarizza et al., 1994) . As expected, the depolarization of mitochondria is induced gradually in YT102 (Mgmt À/À ) cells after treatment with MNU (Figure 6b ). However, no such depolarization was observed with KH101 (Mgmt
). To obtain further evidence that KH101 mutant cells are defective in a certain step in the process of apoptosis, we measured caspase-3 activity. Figure 6c shows levels of caspase-3 activity after treatment of the three types of cells with 0.4 mM MNU. Caspase-3 activity of YT102 cells increased three times the level of the untreated cells, whereas no increase was observed with YT103 cells. In KH101 cells, the level of caspase-3 activity after MNU treatment was as low as that of the untreated control. These results further support the notion that KH101 cells might have a defect in a certain step of the O 6 -methylguanine-induced apoptosis pathway.
Cytoplasmic localization of EGFP-fused MAPO1 proteins
To analyse the subcellular localization of the MAPO1 protein, we have cloned the full-length mouse Mapo1 cDNA and expressed EGFP-fused mMAPO1 protein in YT102 cells. As shown in Figure 7a , transiently expressed mMAPO1 protein is predominantly present in the cytoplasm. The cytoplasmic localization of mMAPO1 protein did not dramatically change even after treatment of cells with MNU. To assess whether this is the case for the highly conserved human ortholog, we also obtained the human cDNA for the gene and expressed EGFP-fused hMAPO1 protein in HeLa MR cells (Figure 7b) . Similarly, the cytoplasmic localization of hMAPO1 was observed and it was found to be unaffected by the MNU treatment.
Discussion
There are two distinct types of DNA lesions that induce apoptosis: modified bases that cause base mispairing and bulky DNA lesions that block DNA replication. The former requires MMR proteins for induction of apoptosis, whereas the latter induces apoptosis even without the function of such proteins. O 6 -Methylguanine, produced in DNA by the action of simple alkylating agents, does not prevent the progression of DNA replication forks and apparently represents the former class DNA lesion (Singer et al., 1989; Haracska et al., 2000) . During DNA replication, O 6 -methylguanine (O 6 -meG) can pair with thymine as well as cytosine, and unless repaired, the resulting O 6 -meG:T mispair would lead to mutations after next round of replication. To suppress such an outcome, organisms have been equipped with a mechanism for eliminating cells carrying mutation-evoking DNA lesions. The MMR protein complex apparently acts as a molecular device to detect such lesions. The MutSa, consisting of MSH2 and MSH6, and PCNA complex first recognizes O 6 -meG:T mispair in DNA and then MutLa, composed of MLH1 and PMS2, binds to the initial complex. The formation of the mismatch recognition complex is indispensable for the activation of DNA damage signaling as well as the induction of apoptosis (Hidaka et al., 2005; Yoshioka et al., 2006; Sanada et al., 2007) .
The precise molecular mechanism of signal transduction downstream of mismatch recognition still remains to be determined. As many proteins would be involved in this process, we have initiated the present study to identify such proteins by gene-trap mutagenesis screening. As a selectable marker for the gene trap, a promoterless hygromycin B resistance gene placed near a splicing acceptor and an IRES sequences was used. This allowed efficient expression of the marker, when it was integrated into any region of actively transcribed genes to be mutated. Among Hyg r cells selected, candidate clones could be obtained that might have defects in an apoptosis-related process. In this way, we were able to identify Mapo1, which turned out to be a novel gene involved in O 6 -methylguanine-induced apoptosis. The Mapo1 encodes a protein with a molecular mass of 125.6 kDa, carrying no characteristic functional motifs. The MAPO1 sequence, however, has the highly conserved amino-and carboxyl-terminal domains present in various multicellular organisms A new apoptosis-inducing protein, MAPO1 K Komori et al ranging from humans to nematode, but not in microorganisms including yeast. This evolutional conservation might reflect its possible biological significance on the apoptosis in multicellular organisms.
In the present study, we show that Mapo1 mutation renders the cells significantly resistant to MNU, although it does not dramatically affect its sensitivity to the killing effect caused by MMS, ACNU, etoposide or UV irradiation (Figure 2) . Importantly, even when the Mapo1-defective KH101 cells are treated with MNU, the depolarization of the mitochondrial membrane and caspase-3 activation, hallmarks of apoptosis induction, are significantly suppressed. As the phosphorylation of p53, CHK1 and histone H2AX, downstream targets of ATR kinase, is nevertheless observed in KH101 cells after MNU treatment (Figure 6 ), the MAPO1 protein, which is localized in the cytoplasm (Figure 7) , is not likely to be involved in the nuclear translocation of MutSa complex (Christmann and Kaina, 2000) nor in the activation of MNU-induced DNA damage signaling. These results suggest that MAPO1 may play a role in a certain step(s) of the signal-transduction pathway of apoptosis, induced by the O 6 -methylguanine, that would activate the apoptotic function of the mitochondria.
It is remarkable that the Mapo1 mutation exerts its effect even when one of the alleles is intact. KH101 (Mgmt
) cells exhibit a significantly higher level of resistance to MNU than YT102 (Mgmt
We have also shown that MNUinduced apoptosis, as measured by an increase in the sub-G1 population, is significantly suppressed when the expression level of Mapo1 is reduced to half its normal level by siRNA treatment. This haploinsufficient character of the Mapo1 gene is reminiscent of the phenomenon observed with MMR-related genes. Mgmt
þ /À cells, which carry almost half the amount of MLH1 protein in comparison with Mlh1 þ / þ cells, are substantially resistant to the killing action of MNU than are Mgmt (Kawate et al., 2000; Cejka et al., 2003; Takagi et al., 2003) . This haploinsufficient nature may be related to the fact that MLH1 protein forms a heterodimer with PMS2 to form a MutLa complex (Li and Modrich, 1995) . MutLa further binds to MutSa, which is composed of MSH2 and MSH6, and participates in the recognition of mismatch bases in DNA to initiate the apoptotic reaction. Thus, these mismatch recognition proteins act in a stoichiometric manner, rather than in a catalytic one, in inducing the apoptotic signal. As the Mapo1 exhibits a similar phenotype, it may exert its function by forming a complex with other components, rather than by acting in a catalytic manner or by changing the localization of the protein.
To obtain further insight into the Mapo1 function, it is necessary to establish a cell line defective in both of the alleles of the gene. The neomycin selection method, which is usually used to isolate such clones, cannot be applied to the present study, as the neomycin-resistant marker was already introduced into the parental strain to knockout the Mgmt gene. Other strategies are now being applied to isolate such doubly deficient cells that might show a higher level of resistance to the MNU treatment.
Materials and methods
Cell lines and cell culture YT102 (Mgmt
) are cell lines established, by expressing SV40 T antigen, from primary cells consisting of fibroblasts derived from the lung tissue of Mgmt and Mgmt Mlh1-knockout mice, respectively (Takagi et al., 2003) . YT102M is a derivative of YT102 that carries the expression vector, pIREShyg2:Mgmt (Takagi et al., 2003) , to stably express human MGMT. The cells were cultivated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) at 37 1C in 5% CO 2 .
Gene-trap mutagenesis and screening for MNU r clones The retrovirus vector, pLHDU3L, which carries the hygromycin B resistance gene, was constructed for the gene-trap mutagenesis. The promoter region in 3 0 LTR of a retroviral vector, pDON-AI (Takara Bio Inc., Ohtsu, Japan), was removed by AflII and XbaI digestion followed by self-ligation. The SV40 promoter and the neomycin resistance gene were removed from the vector by digestion with SalI and XhoI, and then the loxP 2 -containing fragment, which was excised from the pBS246 vector (Invitrogen, Carlsbad, CA, USA) by NotI digestion, was inserted into the site after blunt ending. A DNA fragment containing synthetic intron (IVS), IRES, hygromycin B resistance gene and poly A signal sequences was isolated from pIREShyg2 vector (Clontech, Mountain View, CA, USA), and then inserted into the EcoRV site in the loxP 2 region of the retroviral vector. The resulting pLHDU3L vector was introduced into CMP34 (Takara Bio Inc.) cells by using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. After incubation of the cells for 1.5 days at 33 1C, the retroviral particles carrying the gene-trap construct in the medium were recovered and filtered. Approximately 1.5 Â 10 7 of YT102 cells grown on twenty 10-cm dishes were infected with the retrovirus and incubated for 15 h. The cells were further cultivated in a virus-free fresh medium for another day and then selected in a medium containing 0.6 mg/ml of hygromycin B for 55 h. After washing with phosphate-buffered saline (PBS) three times, the cells were treated with 0.4 mM MNU in serum-free medium for 1 h and further incubated in complete medium containing 10% FBS. Colonies formed were subjected to a quantitative cell survival assay with various concentrations of MNU. Finally, MNU r mutant cell lines were thus obtained.
Immunoblotting
Whole cell extracts were prepared by the lyses of cells with 2 Â SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (120 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 200 mM dithiothreitol and 0.002% bromophenol blue) and then subjected to SDS-PAGE and electroblotted onto a PVDF membrane (Bio-Rad, Hercules, CA, USA). Detection was performed using an ECL Plus or Advance western blotting detection kit (GE Healthcare, Buckinghamshire, UK 
Survival of cells treated with MNU, MMS, ACNU etoposide and UV-C
The cells were treated with various concentrations of MNU, MMS or ACNU in serum-free medium for 1 h, etoposide in a medium containing 10% FBS for 12 h, or irradiated with different doses of UV-C. After cultivation with a medium containing 10% FBS for 6 days, the number of colonies was counted and the survival rate was calculated.
Measurement of mutant frequency
The cells were treated with 0 or 0.4 mM MNU as described above and incubated for 4 days. Then, the cells were placed in a medium containing 2 mM ouabain for 10 days. After staining, the number of resistant colonies was counted. In parallel, a cell suspension containing about 500 cells was seeded in several dishes and the number of viable cells was counted.
Analyses of the disrupted gene by PCR For inverse PCR, 10 mg of genomic DNA prepared from KH101 mutant cells was digested with BamHI and BglII, or HindII restriction enzymes. Precipitated DNA was resuspended in 1 ml of buffer (66 mM Tris-HCl; pH 7.6, 6.6 mM MgCl 2 , 10 mM dithiothreitol and 0.1 mM ATP) and incubated at 16 1C overnight after adding 1750 U of T4 DNA ligase (Takara Bio Inc.). By using the DNA as a template, 5 0 -and 3 0 -junctions between the disrupted gene and the vector DNA were amplified by PCR with two primer sets designed for the vector sequence, GS1: 5 0 -AGCTTACCTCCCGGTGGTGGG TCGGTGGTC-3 0 and DON1: 5 0 -GCGGGGGCGACTTCG GCTCACAGCGCGCCC-3 0 or US1: 5 0 -CTTGTGGTCTCG CTGTTCCTTGGGAGGGTC-3 0 and UR1: 5 0 -GGGGCACC CTGGAAACATCTGATGGTTCTC-3 0 , respectively. The DNA fragments amplified were cloned into a pGEM-Teasy vector (Promega, Madison, WI, USA). The nucleotide sequences of the clones were determined and analysed in NCBI GenBank.
For the detection of the mutant allele, DNA fragments specific for the disrupted Mapo1 gene or for the intact gene were amplified by PCR, using primer sets, G5 0 þ V5 0 and V3 0 þ G3 0 , or G5 0 þ G3 0 , respectively. The nucleotide sequences of PCR primers are G5
Measurement of gene expression by real-time PCR Total RNA was prepared from cells grown on a six-well plate using the RNeasy Mini kit (Qiagen, Hilden, Germany) and were used to synthesize cDNAs by using PrimeScript Reverse Transcriptase (Takara Bio Inc.). Real-time PCR was performed with a light cycler (Roche, Mannheim, Germany) using SYBR Premix Ex Taq (Takara Bio Inc.). The PCR primers for a Mapo1 gene, pMapo1-F and pMapo1-R, and for a Gapdh gene as a reference, pmGapdh-F and pmGapdh-R, were purchased from Takara Bio Inc. and the nucleotide sequences are pMapo1-F, 5 0 -GCACACAGCACACCTGTTGA-3 0 ; pMapo1-R, 5 0 -GCGCTGGTAACTGCTGGAA-3 0 ; pmGapdh-F, 5 0 -AAATGGTGAAGGTCGGTGTG-3 0 ; pmGapdh-R, 5 0 -TGA AGGGGTCGTTGATGG-3 0 .
siRNA transfection Stealth RNAi for the Mapo1 sequence (siMapo1), 5 0 -CA GAAAGCAGAGGATGTTCCTATTA-3 0 , was purchased from Invitrogen. After culturing 1 Â 10 5 cells in a six-well plate for 1 day, the cells were transfected with 20 nM siRNA, using the Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's protocol. For the control transfection, Stealth RNAi Negative Control Medium GC Duplex (Invitrogen) was used.
Mitochondrial membrane depolarization assay About 2 Â 10 5 cells were washed with PBS and treated with 0.48 mM MNU for 1 h. The doses of the drugs correspond to six lethal hits for YT102 cells, as calculated from the survival curves. The cells were further incubated in complete medium and collected at 0, 12, 24, 36 and 48 h after the treatment with MNU. The mitochondrial membrane potential assay was performed using the MitoProbe DiOC2(3) Assay kit (Invitrogen), as described earlier (Takagi et al., 2008) .
Molecular cloning of Mapo1 cDNAs
To clone mouse Mapo1 cDNA, RT-PCR reactions were carried out to amplify four parts of cDNA with overlapping sequences using cDNAs, synthesized from total RNA prepared from YT102 cells, as templates. The four cDNA fragments were connected to each other at the internal restriction sites and the full-length mouse Mapo1 cDNA was thus generated. The human Mapo1 cDNA (KIAA1450) was obtained from the Kazusa DNA Research Institute (Kisarazu, Japan).
Expression of EGFP-fused MAPO1 protein and microscopic analysis
To construct plasmids to express MAPO1 proteins fused with EGFP at the C-terminal regions, we introduced mouse and human Mapo1 cDNA together with the EGFP gene into EcoRV and NotI site of pIRESpuro2 (Clontech) plasmid. To express the EGFPfused MAPO1 proteins, 0.8 mg of plasmid DNAs was transfected using Lipofectamine 2000 into YT102 (for mouse) or HeLa MR (for humans) cells growing in 24-well plates according to the manufacturer's instructions. The cells were treated with or without 0.4 mM MNU for 1 h at 24 h after transfection. After another 24-h incubation, the cells were washed with PBS and stained with 10 mM of Hoechst33342 (Invitrogen) and fluorescent signals were observed by fluorescent microscopy (Nikon, Tokyo, Japan).
Other methods
Flow cytometric analysis and of caspase-3 activity assay were performed as described earlier (Hidaka et al., 2005) .
